Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH, 44195, USA.
Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Dig Dis Sci. 2022 Jun;67(6):2677-2687. doi: 10.1007/s10620-021-07048-5. Epub 2021 May 23.
The data on hepatocellular carcinoma (HCC) patients without liver cirrhosis is scarce.
To study the epidemiology, underlying etiology and fibrosis distribution in noncirrhotic HCC and compare the survival outcomes to cirrhotic HCC.
We conducted a retrospective study including all adult patients diagnosed with HCC at two US tertiary academic centers from 2000 to 2015. Univariable and multivariable Cox regression analyses were performed to evaluate the variables associated with patient survival.
Two thousand two hundred and thirty-seven HCC patients were included in the final analysis, of which, 13% had no liver cirrhosis. The most common underlying liver disease in non-cirrhotic patients was cryptogenic cause (40%), followed by nonalcoholic fatty liver disease (NAFLD) (25.2%) and hepatitis C (19%). The percentage of F0-F1, F2, and F3 was 72%, 17%, and 11% (cryptogenic cause); 69%, 12%, and 19% (NAFLD); 50%, 17%, and 33% (alcohol); 33%, 39%, and 28% (hepatitis B); 20%, 40%, and 40% (hemochromatosis); and 12%, 40%, and 48% (hepatitis C), respectively. In non-cirrhotic compared to cirrhotic patients, the tumor was more likely to be larger and fell outside Milan criteria (all p < 0.001). Cirrhotic patients had significant shorter survival than non-cirrhotic patients (p < 0.001). On the multivariable analysis, having liver cirrhosis (HR 1.48; 1.21-1.82, p < 0.001), combined viral hepatitis and alcohol use (HR 1.51; 1.23-1.88, p < 0.001), morbid obesity (HR 1.31; 1.01-1.69, p = 0.040) and underweight (HR 2.06; 1.27-3.34, p = 0.004) were associated with worse patient survival.
The fibrosis distribution in non-cirrhotic HCC differed among each etiology of liver diseases. Despite more advanced HCC, patients without cirrhosis had significantly longer survival than those with cirrhosis.
目前关于无肝硬化的肝细胞癌(HCC)患者的数据较少。
研究非肝硬化 HCC 的流行病学、潜在病因和纤维化分布,并将其生存结果与肝硬化 HCC 进行比较。
我们进行了一项回顾性研究,纳入了 2000 年至 2015 年在美国两家三级学术中心诊断为 HCC 的所有成年患者。采用单变量和多变量 Cox 回归分析评估与患者生存相关的变量。
2237 例 HCC 患者纳入最终分析,其中 13%无肝硬化。非肝硬化患者最常见的潜在肝病病因是不明原因(40%),其次是非酒精性脂肪性肝病(NAFLD)(25.2%)和丙型肝炎(19%)。F0-F1、F2 和 F3 的比例分别为 72%、17%和 11%(不明原因);69%、12%和 19%(NAFLD);50%、17%和 33%(酒精);33%、39%和 28%(乙型肝炎);20%、40%和 40%(血色病);12%、40%和 48%(丙型肝炎)。与肝硬化患者相比,非肝硬化患者的肿瘤更有可能更大,且超出米兰标准(均 p<0.001)。肝硬化患者的生存时间明显短于非肝硬化患者(p<0.001)。多变量分析显示,存在肝硬化(HR 1.48;1.21-1.82,p<0.001)、合并病毒性肝炎和酒精使用(HR 1.51;1.23-1.88,p<0.001)、病态肥胖(HR 1.31;1.01-1.69,p=0.040)和体重过轻(HR 2.06;1.27-3.34,p=0.004)与患者生存不良相关。
非肝硬化 HCC 的纤维化分布在不同病因的肝病中存在差异。尽管 HCC 更晚期,但是无肝硬化的患者的生存时间明显长于有肝硬化的患者。